ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting
March 29 2016 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
the presentations related to the Company’s technology portfolio to
be made at the American Association for Cancer Research (AACR)
annual meeting being held April 16-20, 2016 in New Orleans, LA.
ImmunoGen is a recognized leader in the ADC field and invests in
new technologies to further extend the types of cancers potentially
treatable with this therapeutic approach. Presentations at AACR
relate to:
- Cancer-killing
agent/linker innovations – ImmunoGen and partner ADCs in the
clinic today all utilize one of the Company’s tubulin-acting
maytansinoid agents attached to an antibody using an engineered
ImmunoGen linker. The Company has developed a new class of
cancer-killing agents – DNA-alkylating IGNs – and multiple
purpose-driven linkers and will report new IGN/linker data
(abstract #2959).
- Site-specific
attachment innovations – Preclinical studies suggest
advantages to site-specific attachment of IGNs, and the Company
will have several presentations about site-specific technology
innovations (abstracts #2960, #2965, and #2967).
- Partner program
preclinical research – In addition to ImmunoGen’s product
programs, nine healthcare companies have licensed rights to utilize
Company technology to develop ADCs for specific targets. Two
partners will report preclinical ADC data (abstracts #872, #1197,
#1198, and #2974).
Additional information – including presentation schedule, titles
and full abstracts – can be found at www.aacr.org
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is in Phase 2 testing for the treatment of folate
receptor α-positive ovarian cancer. ImmunoGen's ADC technology is
used in Roche's marketed product, Kadcyla®, and in programs in
development by partners Amgen, Bayer, Biotest, CytomX, Lilly,
Novartis, Sanofi and Takeda. More information about the Company can
be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to new
technologies. A review of these risks can be found in ImmunoGen’s
Annual Report on Form 10-K for the fiscal year ended June 30, 2015
and other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160329006477/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Michael Lampe,
484-575-5040michael@michaellampeconsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024